SEC Filing Summary: AVI BioPharma, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2002, for AVI BioPharma, Inc. (Note: The input metadata referenced "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is a development-stage biopharmaceutical firm focused on research and development (R&D) with no material product revenues. It has been unprofitable since its inception in 1980.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2002 | Six Months Ended June 30, 2002 | Balance Sheet (June 30, 2002) |
|---|---|---|---|
| Revenues | $197,691 | $435,386 | N/A |
| Net Loss | $(10,497,859) | $(18,313,952) | N/A |
| Loss Per Share (Basic/Diluted) | $(0.40) | $(0.74) | N/A |
| Operating Expenses | $8,119,801 | $16,253,440 | N/A |
| Cash & Cash Equivalents | N/A | N/A | $13,445,102 |
| Short-term Securities | N/A | N/A | $16,234,538 |
| Total Current Assets | N/A | N/A | $30,265,576 |
| Total Current Liabilities | N/A | N/A | $3,955,415 |
| Accumulated Deficit | N/A | N/A | $(105,532,959) |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased to $197,691 for the quarter (from $87,264 in Q2 2001) and $435,386 for the six months (from $103,244 in 2001), driven by higher grants and research contract revenues.
- Expense Surge: Operating expenses rose significantly to $8.12 million for the quarter and $16.25 million for the six months. This increase was primarily due to R&D staffing and outside collaboration costs.
- Manufacturing Costs: Approximately $4 million of the quarterly expense increase was attributed to outside contractor GMP manufacturing costs for NEUGENES for Phase III clinical trials of the Resten-NG product.
- Investment Impairment: The company recorded a non-cash write-down of $2,686,956 on its investment in SuperGen, Inc. (a related party) due to an "other than temporary impairment."
- Financing Activity: In the first half of 2002, the company raised approximately $21.7 million in net proceeds from a private equity offering and option exercises.
Guidance, Outlook, and Risks
- Outlook: The company expects to continue incurring losses for the foreseeable future. It does not anticipate material product revenues for at least the next 12 months.
- 2002 Expenditure Guidance: Management revised its 2002 operating expenditure estimate to approximately $25 million (up from an earlier $20 million estimate), largely due to higher-than-expected short-term outside manufacturing costs. Expenditures for 2003 are expected to be less than or equal to the 2002 estimate.
- Liquidity: As of June 30, 2002, the company held $29.7 million in cash, cash equivalents, and short-term securities. Management believes this is sufficient to fund operations for the next 12 months absent new product revenues or partnerships.
- Risks: Key risks include the success of R&D and clinical trials, regulatory approvals, and the need for future capital raises which may be dilutive. The company has no credit facility.
- Corporate Governance: Following the annual meeting, the company dismissed Arthur Andersen LLP as its independent auditor and retained KPMG LLP. A director change also occurred with Nick Bunick resigning and Andrew J. Ferrara being elected.
Investor Verification Checklist
- Capital Runway: Verify if the $25 million 2002 burn rate aligns with current cash balances and if additional financing is imminent.
- SuperGen Investment: Review the status of the SuperGen, Inc. investment and the rationale for the $2.7 million impairment charge.
- Manufacturing Transition: Confirm the timeline for moving NEUGENES manufacturing in-house to reduce the high external contractor costs cited in the filing.
- Auditor Change: Investigate the reasons behind the dismissal of Arthur Andersen and the transition to KPMG.
- Clinical Progress: Monitor the status of the Phase III clinical trials for Resten-NG, as this is the primary driver for potential future revenue.